With another earnings season upon us, the Fool's health-care team is busy making sure investors know what to expect from their favorite companies this quarter, while also maintaining a focus on the long term.

In the following video, health-care bureau chief Brenton Flynn outlines some derivative insights from today's Johnson & Johnson (NYSE:JNJ) earnings call, where he made a number of observations and found implications for Medivation (NASDAQ:MDVN), Zimmer (NYSE:ZMH), Stryker (NYSE:SYK), and potentially Abbott Labs (NYSE:ABT).


Brenton Flynn has no position in any stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson and Zimmer Holdings. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.